Sponsor or institution

Clinical trials and research at Hansoh BioMedical R&D Company

• 22Clinical trials
• 1New in 30 days
• 2Countries

Newest trials

All recruiting trials (22)

• HS-20137: a treatment option for adults with moderate-to-severe plaque psoriasis

  A phase 2 open-label study tests HS-20137 given as 200 mg at weeks 0, 4 and 8 to see if it is safe and helps patients with moderate-to-severe plaque psoriasis.

  Recruiting Phase 2 Hansoh BioMedical R&D Company · Beijing, Beijng · NCT07879885

• HS-20093 with Adebrelimab vs HS-20093 alone in advanced non-squamous NSCLC

  This study tests whether adding adebrelimab to HS-20093 helps patients with advanced non-squamous NSCLC who have already had treatment.

  Recruiting Phase 2 Hansoh BioMedical R&D Company · Wuhan, Hubei · NCT07824882

• HS-20117-2 Injection in Patients With Advanced Solid Tumors (Phase 1)

  This phase 1 study tests HS-20117-2 given under the skin to see how the drug behaves in the body and whether it’s safe for adults with advanced solid tumors.

  Recruiting Phase 1 Hansoh BioMedical R&D Company · Guangzhou, Guangdong · NCT07775703

• HS-20122 combination therapy in NSCLC (Phase 1b)

  A early-stage trial tests whether adding HS-20122 to standard therapies is safe and helps people with locally advanced or metastatic non-small cell lung cancer.

  Recruiting Phase 1 Hansoh BioMedical R&D Company · Guangzhou, Guangdong · NCT07645222

• HS-20110 with bevacizumab and chemotherapy for advanced colorectal cancer

  This trial will test whether adding HS-20110 to bevacizumab plus standard chemotherapy helps adults with advanced colorectal cancer.

  Recruiting Phase 1/2 Hansoh BioMedical R&D Company · Guangzhou · NCT07283367

• How itraconazole affects HS-20093 levels in people with advanced solid tumors

  This test will see if taking oral itraconazole changes how the experimental cancer drug HS-20093 is processed in people with advanced solid tumors who have not responded to standard treatments.

  Recruiting Phase 1 Hansoh BioMedical R&D Company · Changsha, Hunan · NCT07186452

• HS-20093 plus HRS-5041 for advanced prostate cancer

  This phase Ib trial will test whether combining HS-20093, a B7-H3–targeted antibody-drug conjugate, with HRS-5041, an androgen receptor–targeting PROTAC, is safe and tolerable in men with metastatic castration-resistant prostate cancer who have progressed on prior hormonal therapy.

  Recruiting Phase 1 Hansoh BioMedical R&D Company · Shanghai · NCT07115446

• HS-20108 in people with advanced solid tumors

  This Phase 1 study tests HS-20108 given through IV to see if it is safe and can work in people with advanced solid tumors including small cell lung cancer and neuroendocrine carcinoma.

  Recruiting Phase 1 Hansoh BioMedical R&D Company · Shanghai, Shanghai Municipality · NCT06936735

• HS-20122 for adults with advanced solid tumors

  This first-in-human Phase I test will try HS-20122 in adults with advanced solid tumors to find safe dosing, watch for side effects, and look for early signs it helps control tumors.

  Recruiting Phase 1 Hansoh BioMedical R&D Company · Guangzhou, Guangdong · NCT06927570

• HS-20110 for adults with advanced solid tumors

  HS-20110 will be tested for safety and tolerability in adults with advanced solid tumors who have at least one measurable tumor outside the brain.

  Recruiting at 8 sites Phase 1 Hansoh BioMedical R&D Company · Tamarac, Florida and 7 other locations · NCT06892379

• HS-20089 injection for platinum-resistant recurrent epithelial ovarian cancer

  This trial will test whether HS-20089 works better than the doctor's choice of chemotherapy for adults with platinum-resistant recurrent epithelial ovarian cancer.

  Recruiting Phase 3 Hansoh BioMedical R&D Company · Beijing · NCT06855069

• Combination therapy using HS-20093 for advanced metastatic colorectal cancer

  This study is testing a new combination treatment using HS-20093 for people with advanced metastatic colorectal cancer to see if it is safe and effective, especially for those who haven't had treatment before or who didn't respond to standard therapies.

  Recruiting Phase 1 Hansoh BioMedical R&D Company · Hangzhou, Zhejiang · NCT06825624

• Testing HS-20124 for advanced solid tumors

  This study is testing a new treatment called HS-20124 to see if it can help people with advanced solid tumors feel better and fight their cancer.

  Recruiting Phase 1 Hansoh BioMedical R&D Company · Shanghai, Shanghai Municipality · NCT06763159

• Testing HS-20117 with other drugs for advanced solid tumors

  This study is testing a new drug called HS-20117, along with other treatments, to see if it can help people with advanced solid tumors like non-small cell lung cancer and colorectal cancer.

  Recruiting Phase 1 Hansoh BioMedical R&D Company · Tianjin · NCT06621563

• HS-20117 combined with aumolertinib for advanced EGFR‑mutant non-squamous lung cancer

  This tests whether adding the bispecific antibody HS-20117 to aumolertinib helps people with advanced, treatment‑naive, EGFR‑mutant non‑squamous non‑small cell lung cancer live longer or have better tumor control.

  Recruiting at 2 sites Phase 2/3 Hansoh BioMedical R&D Company · Tianjin, Tianjin Municipality and 1 other locations · NCT06417008

• Combination treatment using HS-20089 for advanced solid tumors

  This study is testing a new combination treatment using HS-20089 with other cancer drugs to see if it can help people with advanced solid tumors.

  Recruiting Phase 1 Hansoh BioMedical R&D Company · Shanghai, Shanghai Municipality · NCT06336707

• Investigating HS-20093 combinations for advanced solid tumors

  This study is testing a new treatment called HS-20093 to see if it can help people with advanced solid tumors who haven't had success with other therapies.

  Recruiting Phase 1 Hansoh BioMedical R&D Company · Shanghai, Shanghai Municipality · NCT06332170

• HS-20093 treatment for advanced esophageal cancer and other solid tumors

  This study is testing a new treatment called HS-20093 to see if it can help people with advanced esophageal cancer and other solid tumors feel better.

  Recruiting at 17 sites Phase 2 Hansoh BioMedical R&D Company · Hefei, Anhui and 20 other locations · NCT06112704

• HS-20089 treatment for ovarian and endometrial cancer

  This study is testing a new treatment called HS-20089 to see if it can help people with recurrent or advanced ovarian and endometrial cancer feel better.

  Recruiting at 26 sites Phase 2 Hansoh BioMedical R&D Company · Hefei, Anfei and 27 other locations · NCT06014190

• HS-20093 treatment for head and neck cancer and other solid tumors

  This study is testing a new treatment called HS-20093 to see if it can help people with advanced head and neck cancer and other solid tumors who haven't had success with standard therapies.

  Recruiting at 24 sites Phase 2 Hansoh BioMedical R&D Company · Hefei, Anhui and 24 other locations · NCT06007729

• HS-20093 treatment for patients with relapsed or refractory osteosarcoma and other sarcomas

  This study is testing a new treatment called HS-20093 to see if it can help patients with relapsed or hard-to-treat osteosarcoma and other types of sarcomas feel better.

  Recruiting at 11 sites Phase 2 Hansoh BioMedical R&D Company · Beijing and 10 other locations · NCT05830123

• Testing HS-20089 for advanced solid tumors

  This study is testing a new drug called HS-20089 to see if it can help people with advanced solid tumors that have a specific marker called B7-H4.

  Recruiting Phase 1 Hansoh BioMedical R&D Company · Shanghai, Shanghai Municipality · NCT05263479

Quick answers

How many clinical trials run by Hansoh BioMedical R&D Company are recruiting right now?

22, as of November 12, 2026. 1 of them was first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 2 countries. The most sites are in China (22 trials), United States (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1: 13, Phase 2: 6, Phase 1/2: 1, Phase 2/3: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →